Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2017 Dec 21

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

Minerva Endocrinologica 2017 Dec 21

DOI: 10.23736/S0391-1977.17.02792-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Prolactinomas: how to handle prior to and during pregnancy?

Andrea GLEZER, Marcello D. BRONSTEIN

Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil


PDF  


Prolactinomas are the most common cause of pathological hyperprolactinemia, leading to central hypogonadism and, therefore, a frequent etiology of infertility. Treatment, usually with dopamine agonist (DA), can reverse hyperprolactinemia and hypogonadism, allowing pregnancy in the majority of cases. Bromocriptine is still the DA of choice for such purpose. Important issues in DA-induced pregnancies include fetal exposition, both malformations and neuropsychological development and tumor size increase. Regarding microprolactinomas and intrasellar macroprolactinomas, DA should be withdraw as soon as pregnancy is confirmed. In expansive/invasive macroprolactinomas, DA maintenance should be individualized. Patient follow up includes periodically clinical evaluation, sellar imaging only indicated in the presence of tumor mass effects related symptoms. Neurosurgery, both before and during gestation, is indicated in cases in which DA treatment failed. Breastfeeding is usually allowed. As tumor volume decrease and remission of hyperprolactinemia may occur after pregnancy, serum prolactin levels and tumor status should be reevaluated.


KEY WORDS: Prolactinoma - Pregnancy - Bromocriptine - Cabergoline

top of page

Publication History

Article first published online: December 21, 2017
Manuscript accepted: December 19, 2017
Manuscript received: December 15, 2017

Cite this article as

Glezer A, Bronstein MD. Prolactinomas: how to handle prior to and during pregnancy?. Minerva Endocrinol 2017 Dec 21. DOI: 10.23736/S0391-1977.17.02792-4

Corresponding author e-mail

mdbronstein@uol.com.br